Baxter (BAX) Declares $0.115 Quarterly Dividend; 1.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Baxter Declares Quarterly Dividend
July 29, 2015 4:10 PM EDTDEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.
This dividend represents the new quarterly dividend rate for Baxter following its successful spin-off of its biopharmaceuticals business, Baxalta Incorporated, on July 1, 2015. Over its 84-year history, Baxter has consistently paid a dividend to shareholders and followed a disciplined approach to capital allocation that balances reinvestment in the businesses with returning significant value to shareholders.
''This quarterly dividend is... More
Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance
July 29, 2015 4:05 PM EDTCompany Achieves Significant Milestone with Successful Completion of Baxalta Incorporated Spin-Off, Poised for Profitable Growth
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today reported second quarter financial results that exceeded the companys previously issued guidance, and provided its complete financial outlook for the second half of 2015. The results for the second quarter of 2015 include the companys BioScience business, which was officially spun-off on July 1st and is now operating as a publicly traded biopharmaceutical company, Baxalta Incorporated (NYSE: BXLT).... More
